For the year ending 2025-12-31, TVTX had $34,500K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss from continuing operations | -50,261 |
| Depreciation and amortization | 60,743 |
| Share based compensation | 44,868 |
| In-process research and development | 0 |
| Loss on allowance for inventory | 684 |
| Amortization of debt discount and issuance costs | 1,640 |
| Amortization of discounts on investments | 4,436 |
| Other | 1,457 |
| Accounts receivable | 27,822 |
| Inventory | -5,016 |
| Income taxes | -849 |
| Prepaid expenses and other current and non-current assets | 7,658 |
| Change in lease assets and liabilities, net | -622 |
| Accounts payable | -85 |
| Accrued expenses | 28,840 |
| Deferred revenue, current and non-current | -2,815 |
| Other current and non-current liabilities | -9,700 |
| Net cash provided by (used in) operating activities - continuing operations | 37,784 |
| Net cash (used in) provided by operating activities - discontinued operations | 0 |
| Net cash provided by (used) in operating activities | 37,784 |
| Proceeds from the sale and maturity of marketable debt securities | 323,595 |
| Purchase of marketable debt securities | 237,142 |
| Purchase of intangible assets | 58,157 |
| Payment of milestone | 0 |
| Other | 404 |
| Net cash provided by (used in) investing activities - continuing operations | 27,892 |
| Net cash provided by investing activities - discontinued operations | 0 |
| Net cash provided by investing activities | 27,892 |
| Payment of guaranteed minimum royalty | 2,100 |
| Repayment of 2025 convertible senior notes | 68,904 |
| Proceeds from the issuance of common stock, net of issuance costs | 0 |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | 0 |
| Proceeds from exercise of stock options | 34,745 |
| Proceeds from the issuances under the employee stock purchase plan | 2,792 |
| Net cash (used in) provided by financing activities - continuing operations | -33,467 |
| Net cash used in financing activities - discontinued operations | 0 |
| Net cash (used in) provided by financing activities | -33,467 |
| Effect of exchange rate changes on cash | 2,291 |
| Net increase (decrease) in cash and cash equivalents | 34,500 |
| Cash and cash equivalents, beginning of year | 58,535 |
| Cash and cash equivalents, end of year | 93,035 |
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)